• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Earl Crouch, MD
Norfolk, Va

Arch Ophthalmol. 1987;105(5):611.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—The effectiveness of aminocaproic acid in preventing secondary hemorrhage in traumatic hyphemas has been demonstrated both in a prospective, randomized, double-masked, controlled clinical study¹ and in basic pharmacologic studies.² Three additional clinical studies and one animal model have confirmed these results.^3-6 The secondary hemorrhage rate in these studies with placebo was very similar (28% to 33%). The rate of secondary hemorrhage in those patients treated with aminocaproic acid was 0% to 4%. These scientific studies by different authors at different institutions provide ample scientific evidence to support the use of aminocaproic acid in the treatment of traumatic hyphema.

Dr Romano has suggested the use of systemic steroids in traumatic hyphema treatment to circumvent the problems with aminocaproic acid. Unfortunately, there is little basic pharmacologic research to support his claim. Low concentrations of glucocorticoids have been demonstrated to retard the ability of neutrophils to promote conversion . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?